S. Lim

发表

PEGylated TRAIL ameliorates experimental inflammatory arthritis by regulation of Th17 cells and regulatory T cells

M. Pomper, D. Jo, Yumin Oh, 2017, Journal of controlled release : official journal of the Controlled Release Society.

Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects.

Seung Woo Chung, Y. Byun, Ji-Young Kim, 2021, Journal of controlled release : official journal of the Controlled Release Society.

Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.

M. Pomper, Kwangmeyung Kim, M. Swierczewska, 2015, Journal of controlled release : official journal of the Controlled Release Society.

Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.

Xiaoyuan Chen, Seulki Lee, Kang-Choon Lee, 2011, Biomaterials.

Site-specific PEGylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects.

Y. Byun, K. Choi, Xiaoyuan Chen, 2012, Bioconjugate chemistry.

Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.

Kang-Choon Lee, S. Lim, H. Eom, 2015, Journal of pharmaceutical sciences.

Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice.

Y. Youn, Kang-Choon Lee, S. Lim, 2012, Biological & pharmaceutical bulletin.

Mono-lithocholated exendin-4-loaded glycol chitosan nanoparticles with prolonged antidiabetic effects.

Kwangmeyung Kim, S. Chae, Sohee Son, 2015, International journal of pharmaceutics.

Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution.

Y. Youn, Kang-Choon Lee, S. Lim, 2011, Journal of pharmaceutical sciences.

PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting.

Y. Byun, Xiaoyuan Chen, Seulki Lee, 2012, Journal of controlled release : official journal of the Controlled Release Society.

Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)

Kang-Choon Lee, S. Lim, D. Na, 2016, Expert opinion on therapeutic patents.

Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells

M. Pomper, Kwangmeyung Kim, Y. Byun, 2016, Hepatology.

Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells

M. Pomper, Kwangmeyung Kim, Y. Byun, 2016, Hepatology.